Stud Health Technol Inform. 2025 May 15;327:773-774. doi: 10.3233/SHTI250462.
ABSTRACT
The survival rate for high-risk neuroblastoma remains below 50%. Current monitoring methods are costly, invasive, and stressful for patients. MONALISA will evaluate liquid biopsies as a minimally invasive alternative, to enable frequent sampling and consequently early detection of genetic tumour markers. MONALISA leverages an advanced privacy-preserving data management infrastructure, including the SIOPEN BIOPORTAL, the EUPID Services, and patient reported outcome measures, providing a model for other paediatric cancers.
PMID:40380571 | DOI:10.3233/SHTI250462
AI-Assisted Evidence Search
Share Evidence Blueprint
Search Google Scholar
RAISR4D Evidence Matrix
